The most limiting factor regarding the use of TNF␣ in serum concentrations of mTNF␣ (approximately 1 ng/ml) tumour therapy is systemic toxicity. The expression of were detected only in Ad-mTNF-wt-treated mice, while membrane-bound (nonsecreted) TNF␣ within a tumour both vectors induced substantial disruption of tumour pathmay serve to reduce systemic toxicity while retaining antiology. The wt TNF vector was highly toxic, killing 12 of 16 tumour activity. Two adenovirus (Ad) vectors were conmice at a dose of 5 × 10 8 p.f.u., whereas the Ad-mTNFstructed: (1) Ad-mTNF-wt expressing wild-type murine MEM vector showed low toxicity killing three of 27 at the TNF␣; and (2) Ad-mTNF-MEM expressing a mutant nonsame dose. Both vectors induced partial, and in some secreted (membrane-bound) form. Only the Ad-mTNF-wt cases, permanent tumour regressions, with cured mice disvector induced high levels of TNF␣ secretion in transduced playing protective immunity and specific CTL activity cells (approximately 400 ng/10 6 cells), however, both vecagainst the tumour. These results indicate that the use of tors induced efficient cell surface expression as detected a nonsecreted form of TNF␣ can result in a relatively large by FACS. These vectors were used in tumour immunotherreduction in systemic toxicity with little or no reduction in apy trials in a murine transgenic breast cancer model. High antitumour activity.
Introduction
environment. 2, [7] [8] [9] The third antitumour mechanism is Tumour necrosis factor alpha (TNF␣) was originally disthrough immune activation. TNF␣ is a key mediator of covered through the anticancer activity of sera of mice inflammation, and can rapidly activate neutrophils, treated with endotoxin.
1 It is associated with a wide varmacrophages and NK cells, as well as induce the proiety of responses involving the activation of immune duction of other cytokines (IL-6, IL-1, GM-CSF and ILcells, alterations in the extracellular matrix, antiviral 8) and adhesion molecules. 4, 10 The antitumour activity of activity, cachexia, septic shock and more. 2, 3 TNF␣ is first TNF␣ has been shown to be due, in part, to T cell produced as a cell surface 26 kDa protein, most of which (CD4/CD8) activation and to induction of tumouris then cleaved from the membrane by metalloproteases, specific immunity. [11] [12] [13] to produce the mature secreted 17 kDa form. 2 TNF is Perhaps the major limiting factor preventing the clinisecreted by many cell types including macrophages, lymcal use of TNF␣ in tumour therapy is its induction of phocytes, polymorphonuclear cells, astrocytes and systemic toxicity due to septic shock and cachexia. 4, 14, 15 Kupffer cells. 2, 4 Its expression can be induced by bacterial The use of adenoviruses for delivery of TNF␣ might endotoxins, viruses, parasites, complement, antibody/ serve to circumvent this problem. There are many advanantigen complexes and cytokines. 4 tages to using adenovirus vectors to express potentially TNF␣ can act against tumours in three basic ways. The toxic cytokines for tumour therapy. The vector can profirst is through direct cytotoxicity against tumour cells.
duce high levels of continuous/local expression when Induction of apoptosis is the primary mechanism of directly administered to the tumour site, which could direct cytotoxicity by TNF␣, mediated through engageserve to reduce the systemic side-effects associated with ment of the p55 TNF receptor present on most cell the cytokine, while enhancing the local antitumour types. 2, 5 However, most normal and tumour cells are activity. 16 Furthermore, the so-called first generation resistant to direct killing by TNF␣. 3, 6 The second mechAd vectors only transiently express the transgene, thus anism is through effects on the tumour vasculature. It has avoiding long-term stimulation of the immune been shown that TNF␣ can promote intravascular thromsystem. 17, 18 Two mTNF␣ expressing Ad vectors were used in immunotherapy of a murine transgenic breast cancer model. 19 The first vector expressed the complete wild-diffuse into the circulatory system from the site of production we constructed a second vector which expressed a genetically engineered murine TNF␣ (⌬1-9K11E), first described by Decoster et al, 20 that had been altered to a nonsecreted (membrane-bound) form, to prevent its dissemination. Our results show that both vectors had significant antitumour activity, but that the mutant vector was far less toxic.
Results
Expression of TNF␣ from Ad vector-transduced cells Two vectors have been constructed which express murine TNF␣ (Figure 1b) , the first expressing the complete wild-type mTNF␣ cDNA (Ad-mTNF-wt) and the second expressing a mutant form of mTNF␣ which prevents its enzymatic cleavage from the membrane (AdmTNF-MEM) while retaining bioactivity. 20 The mutant cDNA generated by PCR mutagenesis of the wild-type cDNA, has amino acids one to nine deleted and lysine 11 mutated to glutamic acid.
To measure TNF expression, cells were infected at a multiplicity of infection (MOI) of 50 p.f.u. per cell and culture supernatants were harvested at various times, frozen (−70°C), and later assayed for mTNF␣ activity using a TNF␣-sensitive cell line (A673/6), as described in Materials and methods. Ad-mTNF-wt directed high levels of expression (up to 400 ng/10 6 cells) in human MRC5 and murine MT1A2 cells (Figure 2a) . However, negligible levels of secreted TNF␣ were detected from Ad-mTNF-MEM-transduced cells. Expression of secreted TNF␣ by Ad-mTNF-wt-infected cells was also confirmed by ELISA (data not shown).
To detect membrane-associated TNF, FACS analysis was done on MT1A2 cells transduced with either AdmTNF-wt or Ad-mTNF-MEM (Figure 2b ). Similar levels of expression were detected on the surface of cells transduced with both mTNF␣ vectors (79 and 77% positive, of Ad-mTNF-wt, Ad-mTNF-MEM or control vector (Addl70-3). Blood was taken from mice killed on days 1 and 3 and sera were assayed for mTNF␣ by ELISA. Some Ad-ELISA in homogenized tumour tissue from mice treated with both mTNF␣ vectors (Figure 3b ). Tumour pathology mTNF-wt-treated mice became sick (appeared wasted with ruffled fur and rapid shallow breathing) on day 2 from treated mice was examined to determine if bioactive TNF␣ was present in Ad-mTNF-MEM-treated tumours. and were killed. In addition to blood, tumours were also removed from the animals and snap-frozen or fixed in Haematoxylin and eosin stained tumour sections showed considerable disruption of tumour morphology marked 10% neutral-buffered formalin (NBF) for later histological analysis. High levels of mTNF␣ were detected in the by vast areas of cells undergoing pycnosis within tumours injected with either mTNF␣ vectors, while norserum of mice injected with the Ad-mTNF-wt vector (Figure 3a) , particularly on day 2 when visible signs of mal pathology was observed in Ad-dl70-3 injected tumours ( Figure 4 ). These data demonstrate that the toxicity were most apparent. In contrast, only background levels of mTNF␣ were detected in the serum of membrane-bound mutant is not readily released into the circulatory system, but is present and bioactive in vectormice injected with Ad-mTNF-MEM or Ad-dl70-3, whereas significant levels of mTNF␣ were detected by infected tissues. 
u. of Ad-mTNF-MEM (Ad-MEM) or AdmTNF-wt (Ad-TNF), then killed at 1, 2 or 3 days after injection. Serum was collected from dead mice and assayed for mTNF␣ by ELISA as described in Materials and methods. No murine TNF␣ was detected from mice injected with control (Ad-dl70-3) virus (not shown). Note: error Figure 2 In vitro expression in cells transduced with murine TNF␣ vecbars represent standard error exept where n = 2, in which case the spread tors. (a) Human MRC5 (squares) and murine MT1A2 (derived from pribetween data points is given. (b) Supernatants from homogenized tumours mary transgenic tumour cells, circles) cells were transfected with Adtaken 3 days after injection with 5 × 10 8 p.f.u. of Ad-mTNF-MEM (AdmTNF-wt (closed symbols) or Ad-mTNF-MEM (open symbols) at an MEM), Ad-mTNF-wt (Ad-TNF) or control Ad-dl70-3 (Ad-dl) (n = 1), MOI of 50 p.f.u. per cell (error bars represent standard error). (b) FACS were assayed for mTNF␣ by ELISA, as described in Materials and analysis of membrane-bound mTNF␣ expressed from MT1A2 cells. methods. MT1A2 cells were cultured with no virus (light dotted line), or transduced with control virus (grey line), Ad-mTNF-wt (black solid), or with AdmTNF-MEM (black line) at an MOI of 50 p.f.u. per cell. Isolated cells
The Ad-mTNF-wt vector proved to be quite toxic 
× 10
8 and 1 × 10 9 p.f.u. respectively. However, mice surviving doses of 1 and 5 × 10 8 showed partial or complete tumour regressions, with tumours shrinking to at least half of their original volume before relapsing (12 and 25% Antitumour activity of murine TNF␣ vectors Mice bearing subcutaneous PyMidT tumours were used at 1 and 5 × 10 8 p.f.u., respectively), or completely disappearing (25 and 50% at doses of 1 and 5 × 10 8 p.f.u., in immunotherapy experiments to determine the toxicity associated with a single injection of Ad vectors as well respectively). Conversely the Ad-mTNF-MEM vector showed a substantial reduction in systemic toxicity: only as the effects on tumour progression. Mice were injected intratumorally with various doses of Ad-mTNF-wt, aproximately 11-15% lethality was observed at doses of 5 × 10 8 and 1 × 10 9 p.f.u., respectively. Most importantly, Ad-mTNF-MEM or Ad-dl70-3, after which the tumour volume was monitored weekly. treatment with Ad-mTNF-wt. Typically in cured mice T lymphocyte (CTL) activity. [21] [22] [23] To investigate whether Ad mTNF vector treatment had the same effect, cured tumours disappeared within 3-5 weeks after injection with either vector. Ad-dl70-3-injected mice showed no mice were tested for their ability to reject a secondary challenge with the transgenic tumour cells. Approxitumour response as well as no systemic toxicity. These results show that both wild-type and membrane-bound mately 2 months after the tumour was cleared, two AdmTNF-MEM-treated and three Ad-mTNF-wt-treated mutant mTNF␣ vectors can induce a potent antitumour response, with the mutant form being far less toxic.
mice were challenged with the transgenic middle-T tumour cells (see Materials and methods). All challenged mice were immune to the second injection, while naive Antitumour immunity Immune memory against the transgenic tumour cells mice developed tumours within a normal time frame (approximately 18 days). could provide a mechanism for protection against potential metastasis. In similar studies using Ad vectors
The detection of antitumour immune memory suggested that tumour-specific precursor CTL were present expressing IL-2, IL-4 and IL-12 in this tumour model, we have achieved long-term protection and specific cytotoxic in cured mice. Five months after the second challenge, spleens were removed from Ad-mTNF-MEM-treated fact that high doses of the Ad-mTNF-MEM vector were still toxic to a relatively small proportion of the mice indimice and tested for PyMidT-specific CTL activity. In both mice, strong specific CTL activity was detected against cates that this system is not perfect. There was no dose of the Ad-mTNF-MEM vector that was able to cure mice MT3 cells which express PyMidT ( Figure 5 ). Negative controls included the use of PT 0516 target cells (PyMidT while not causing systemic toxicity; thus the problem of systemic toxicity has not been eliminated. The low levels negative) and anti-CD3-treated splenocytes, both of which generated background levels of 51 Cr release. Also, of toxicity seen in Ad-mTNF-MEM-treated mice could be a result of leakage of intracellular mTNF␣ into the system splenocytes from naive mice showed background levels of activity (not shown).
from dead or dying cells. Alternatively, if some of the vector disseminated from the tumour, toxicity could have been induced by the expression of membrane-bound Discussion mTNF␣, in vital organs such as the liver. It has been previously shown in this laboratory that the injection of subUsing adenovirus vectors to express TNF␣ within a cutaneous tumours with Ad vector can lead to substantial tumour produces a dramatic antitumour response.
expression of the transgene in major organs such as the Unfortunately, direct administration of the vector to the liver. 24 Attempts have been made to assay for TNF␣ in tumour does not adequately prevent the toxicity the livers of treated mice by ELISA, but they were unsucobserved by others (reviewed in Refs 2 and 3). Levels of cessful due to a high background signal. It is also possible the cytokine sufficient to cause a high incidence of morthat the induction of other potentially toxic cytokines, tality are still released into the circulation. To prevent such as IFN␥, could be responsible at least in part for the high levels of circulating TNF we constructed an Ad veclow levels of toxicity induced by Ad-mTNF-MEM. tor which directs the expression of a nonsecreted memWe have not yet fully elucidated the nature of the antibrane-bound form of murine TNF␣, and have demontumour response induced by the mTNF expressing Ad strated the efficacy of using this vector to deliver and vectors. PyMidT tumour bearing mice successfully express this mutant within the tumour tissue, resulting treated with Ad-mTNF-MEM or Ad-mTNF-wt demonin reduced systemic toxicity while retaining antitumour strated long-term immunity by rejecting a challenge with activity. The wild-type TNF␣ vector did seem to have PyMidT tumour cells. This long-term immunity was somewhat more antitumour activity than the mutant likely to be mediated by memory T cells, and indeed, a membrane-bound form at equal doses. This could be due high level of PyMidT-specific CTL activity was detected to a reduced interaction with immune and endothelial in mice tested. Our results are in agreement with precells when using the membrane-restricted form. Howvious findings in this field. In murine systems the adminever, we believe that in this case the benefits of restricted istration of recombinant TNF␣ has been shown to proexposure to TNF␣ outweigh the disadvantages. As well, mote antitumour CTL immunity. 12 In addition, Marincola an increase in the dose of the Ad-mTNF-MEM vector et al 13 showed that implanted methylcholanthrene seems to compensate to a large extent for this slightly induced murine sarcoma cells, engineered to secrete reduced antitumour activity. More importantly, it is clear hTNF␣, showed significant growth inhibition when that large doses of TNF␣ did not enter the circulatory injected into animals which possessed pulmonary metastsystem following Ad-mTNF-MEM administration, while ases of the parental (wild-type) cell type. This inhibition a strong response was still initiated within the tumour. was shown to be CD4 and CD8 cell-dependent by immuThis reduction in circulating TNF correlated with a nodepletion, indicating the involvement of T cells in the reduction in mortality associated with the cytokine. The antitumour activity of TNF␣. Contrary to our results, Karp et al 25 1992 found that only secreted and not membrane-bound human TNF␣-transduced tumour cells prevented tumour growth, albeit there are many differences between our two experimental systems. They used a model involving the subcutaneous injection of retrovirally transduced tumour cell lines (205F and 203 E4) into mice, in contrast to our model of directly injecting pre-established PyMidT tumours with Ad vectors. However, the most notable difference between the two systems is their use of human rather than murine TNF␣. Most TNF␣ studies in the mouse have been done using human TNF␣. Much of this was done before the species specificity of the cytokine was fully understood. Human TNF␣ does not bind the murine p75 TNF receptor, but does bind the p55 receptor. [26] [27] [28] One advantage to the use of human TNF␣ in the murine system is the lack of systemic toxicity. It has been bound. In fact it appears that the p55 rather than the p75 TNFR is more strongly involved in the induction of sysmTNF␣ cDNA(⌬1-9/K11E) was constructed using PCR mutagenesis (Figure 1a) . The gene was amplified from temic toxicity. [29] [30] [31] The p75 TNF receptor (TNFR) is involved in proliferative and proinflammatory signals, as the circular plasmid pUCmTNF␣ using the primers AB7330 (5′TGTGAGGGTCTGGGCCATAGA) and well as TNF-mediated activation of T cells. 5, 28, 32 As one would predict, hTNF␣ does not activate murine T cell AB7329 (5′GACGAGCCTGTAGCCCACGTCGTAGCA) which primed PCR replication leftward and rightward lines in vitro. 28 It has been demonstrated that the p75 receptor is the dominant TNFR in human lymphoid outside the deletion respectively (AB7329 contained the point mutation K11E), and Vent polymerase (New tissue, and in particular, human tumour infiltrating lymphocytes (TIL) were found to express exclusively the p75
England Biolabs, Mississauga, Ontario, Canada). The mutated linear product was self ligated to generate the TNFR.
33,34 Therefore, we predict that the use of murine TNF␣ in a murine system would be a better model for plasmid p⌬1-9K11E, then cut with XbaI (Boehringer Mannheim, Laval, Quebec, Canada) to isolate the altered the behaviour of human TNF␣ in the human system, since the full range of physiological effects are induced. 2 cDNA, which was inserted into pMH4 (as above) to yield pmTNF-MEM. Sequence analysis confirmed the presence The immunological activity of transmembrane TNF␣ may also be of particular interest. It has been suggested of the deletion/mutation and the absence of any undesired PCR related mutations. These plasmids were later that the membrane-bound form of TNF␣ is the major activator of the p75 TNF receptor on T cells, and even procotransfected with pBHG10 using the calcium phosphate method to obtain the desired Ad viral vectors, Ad-mTNFvides a costimulatory signal to B cell when expressed on T helper cells.
35,36 A membrane-bound mutant of human wt and Ad-mTNF-MEM, containing the wild-type and mutant mTNF␣ cDNAs, respectively. 40 Adenoviral vec-TNF␣ has been constructed by Perez et al. 37 This human mutant varies from the murine mutant, used in this tors were isolated and propagated in 293 cells as previously described. 40 Ad-dl70-3 which has a deletion in E1 study, in that amino acids one to 12 were deleted and there are no point mutations. It was found to be nonand a deletion/substitution in E3, was used as a negative control vector. 41 All viruses used were purified by bandsecreted and retained the ability to signal cell death through cell to cell contact with sensitive cells. It is coning in CsCl gradients.
40 ceivable that such a mutant could be useful in the treat-TNF␣ bioassay ment of human cancers. However, as with other poten-
The bioassay used to quantify secreted TNF activity meatially toxic cytokine therapies, combinations with other sured direct killing of a sensitive cell line (A673/6). Cells cytokines (IL-2, IL-12, IFN␥ etc) may improve the effecwere dispensed into 96-well plates (2.5 × 10 4 cells in 50 tiveness of the treatment. Work in this area is presently l medium per well) and incubated overnight at 37°C ongoing in our laboratory as well as in others.
(approximately 20 h). The next day the medium was replaced with 40 l of cell culture medium plus soybean trypsin inhibitor (SBTI) (100 g/ml) and cycloheximide
Materials and methods
(20 g/ml). Ten microlitres of the standards or samples were added to the microtitre wells and incubated at 37°C Cell culture overnight (approximately 18 h). Afterwards, 10 l of 5 All cell culture media and reagents were purchased from mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazol-GIBCO (Mississauga, Ontario, Canada) except for Fungiium bromide (MTT) was added to each well, and the zone which was purchased from Squibb (Montreal, Queplates were incubated for 4 h, after which 50 l of 50% bec, Canada). MRC5 cells (ATCC CCL-171; Rockville, dimethyl formamide (20% SDS, pH 4.7) was added. Fol-MD, USA) were cultured in minimal essential medium lowing an additional overnight incubation, the OD 570 was (␣-MEM) supplemented with 2 mm l-glutamine, 100 measured, and the TNF␣ concentration calculated with U/ml penicillin, 0.1 mg/ml streptomycin, 2.5 g/ml reference to the OD 570 obtained from serial dilutions of a Fungizone, and 10% fetal bovine serum (FBS). 293 Cells standard TNF␣ recombinant stock solution. Cycloheximand MT1A2 cells (derived from primary transgenic ide, SBTI, MTT and the recombinant murine TNF␣ used PyMidT expressing tumour cells) were cultured in supas the standard were purchased from Sigma (St Louis, plemented MEM F11 (as above). 19, 22, 38 PT 0516 cells (a non-MO, USA). transformed murine kidney cell line, PyMidT negative) and MT3 cells (a murine kidney cell line, derived by FACS analysis transduction of PT 0516 cells with the PyMidT cDNA) were MT1A2 cells were transduced at an MOI of 50 p.f.u. per cultured in Dulbecco's MEM supplemented as above. In cell with Ad-mTNF-wt, Ad-mTNF-MEM, Ad-dl70-3 addition, MT3 cells were cultured in G418 (400 g/ml) (E1/E3-deleted control virus) or uninfected (mock). until the time of use. The TNF␣-sensitive A673/6 human Twenty-four hours after infection the cells were harcell line (obtained from Dr Jean Marshall, McMaster Univested and resuspended in MEM supplemented with 20 versity, Hamilton, Ontario, Canada) was cultured in ␣-mm Hepes for FACS analysis. Cells were stained with rat MEM supplemented with 100 U/ml penicillin, 0.1 mg/ml anti-TNF␣ monoclonal antibody purchased from Immustreptomycin and 5% FBS.
nocorp Science (Montreal, Quebec, Canada), followed by FITC-anti-rat-IgG (Southern Biotechnology Associates,
Vector construction
Birmingham, AL, USA). Viable cells were gated for analyThe murine TNF␣ cDNA (pUCmTNF␣) was kindly sis by exclusion of propidium iodide (PI)-positive donated by Dr Graeme Dougherty (Terry Fox Laboratory (dead) cells. Vancouver, British Columbia, Canada). The cDNA was inserted into pMH4 placing TNF transcription under the Tumour studies Transgenic mice carrying the PyMidT oncogene under control of the MCMV promoter and the SV40 poly A signal (pmTNF-wt). 39 A deletion/point mutation of the the mouse mammary tumour virus promoter/enhancer (MMTV) were generated by Guy et al. 19 Breast tumours in V-bottomed microtiter plates at 37°C. As an additional negative control, anti-CD3 antibody-treated wells from transgenic females were explanted, and mechanically homogenized in collagenase (0.025% w/v)/dispase (hamster anti-mouse CD3 (145-2C11) ascites at a 1:8 dilution, 10 l per well) were also used. The percentage (0.25% w/v) (Boehringer Mannheim, Laval, Quebec, Canada). Tumour cells were then cultured in MEM F11 specific chromium release was then determined: plus 10% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 2 mm l-glutamine, and 2.5 g/ml Fungizone for (Experimental release − spontaneous release) × 100 (Maximum release − spontaneous release) 24-48 h at 37°C (until confluent). The cultures were trypsinized (0.1% trypsin, 1.06 mm EDTA; Sigma), washed Spontaneous and maximum release were determined by and resuspended in phosphate-buffered saline (PBS), incubating target cells with medium alone or with 1 n then injected subcutaneously (1 × 10 6 cells in 200 l PBS HCl, respectively. per animal) into the right hind flanks of syngeneic FVB mice (Charles River, Canada NCIC and WJM is an MRC Scientist. All PCR primer synthesis and DNA sequencing was done at the Mobix CenmTNF␣ ELISA tral Facility, McMaster University, Hamilton, Ontario. Blood from killed mice was collected on days 1 and 3 after Ad vector injection (some Ad-mTNF-wt mice were killed on day 2 due to sickness), and the serum was snap-
